Skip to Content

15 Results Found

  • Article
  • Open Access
448 Views
12 Pages

Growth Patterns in MPS IVA and MPS IIIA: A Longitudinal Single-Center Study

  • Lior Carmon,
  • Majd Nassar,
  • Daphna Idan,
  • Dar Leifman and ,
  • David Shaki,
  • Siham Elamour,
  • Eli Hershkovitz,
  • Neta Loewenthal,
  • Alon Haim and
  • Orna Staretz Chacham
  • + 5 authors+ 0 author

28 May 2026

Background/Objectives: Mucopolysaccharidoses (MPS) are lysosomal storage disorders characterized by impaired glycosaminoglycan degradation, leading to multisystem involvement and progressive growth impairment. Longitudinal growth data in MPS IVA and...

(This article belongs to the Section Clinical Pediatrics)
  • Article
  • Open Access
13 Citations
8,609 Views
28 Pages

An Engineered sgsh Mutant Zebrafish Recapitulates Molecular and Behavioural Pathobiology of Sanfilippo Syndrome A/MPS IIIA

  • Alon M. Douek,
  • Mitra Amiri Khabooshan,
  • Jason Henry,
  • Sebastian-Alexander Stamatis and ,
  • Florian Kreuder,
  • Georg Ramm,
  • Minna-Liisa Änkö,
  • Donald Wlodkowic and
  • Jan Kaslin
  • + 4 authors+ 0 author

Mucopolysaccharidosis IIIA (MPS IIIA, Sanfilippo syndrome type A), a paediatric neurological lysosomal storage disease, is caused by impaired function of the enzyme N-sulfoglucosamine sulfohydrolase (SGSH) resulting in impaired catabolism of heparan...

(This article belongs to the Special Issue Modeling Neurological Disorders in Experimental Animals: New Insights and Emerging Roles)
  • Article
  • Open Access
6 Citations
5,070 Views
16 Pages

1 December 2017

Mucopolysaccharidosis III type A (MPS IIIA; Sanfilippo syndrome), a genetic lysosomal disorder causing a deficiency of heparan N-sulfatase (HNS), leads to progressive cognitive decline from an early age. An effective enzyme replacement therapy (ERT)...

(This article belongs to the Section Molecular Pathology, Diagnostics, and Therapeutics)
  • Article
  • Open Access
9 Citations
5,569 Views
27 Pages

Increased Alveolar Heparan Sulphate and Reduced Pulmonary Surfactant Amount and Function in the Mucopolysaccharidosis IIIA Mouse

  • Tamara L. Paget,
  • Emma J. Parkinson-Lawrence,
  • Paul J. Trim,
  • Chiara Autilio and ,
  • Madhuriben H. Panchal,
  • Grielof Koster,
  • Mercedes Echaide,
  • Marten F. Snel,
  • Anthony D. Postle and
  • Sandra Orgeig
  • + 7 authors+ 2 authors

8 April 2021

Mucopolysaccharidosis IIIA (MPS IIIA) is a lysosomal storage disease with significant neurological and skeletal pathologies. Respiratory dysfunction is a secondary pathology contributing to mortality in MPS IIIA patients. Pulmonary surfactant is cruc...

(This article belongs to the Special Issue Lysosomal Storage Disorders)
  • Article
  • Open Access
1,562 Views
12 Pages

Clinical and Molecular Characterization of Pakistani Mucopolysaccharidosis Families with SGSH and GALNS Deficiencies

  • Farheen Nasir Awan,
  • Shumaila Zulfiqar,
  • Liza Eiman,
  • Maria Asif and ,
  • Muhammad Sajid Hussain,
  • Niklas Dahl,
  • Shahid Mahmood Baig and
  • Hirotsugu Oda
  • + 3 authors+ 0 author

31 March 2026

Background: Mucopolysaccharidoses (MPS) are rare lysosomal storage disorders caused by deficiencies in glycosaminoglycan (GAG)-degrading enzymes, leading to progressive multisystem involvement. Methods: We evaluated two unrelated consanguineous Pakis...

(This article belongs to the Section Human Genomics and Genetic Diseases)
  • Article
  • Open Access
12 Citations
3,868 Views
15 Pages

Natural History and Molecular Characteristics of Korean Patients with Mucopolysaccharidosis Type III

  • Min-Sun Kim,
  • Aram Yang,
  • Eu-seon Noh,
  • Chiwoo Kim and ,
  • Ga Young Bae,
  • Han Hyuk Lim,
  • Hyung-Doo Park,
  • Sung Yoon Cho and
  • Dong-Kyu Jin
  • + 4 authors+ 0 author

21 April 2022

Background: Mucopolysaccharidosis type III (MPS III) is an autosomal recessive lysosomal storage disorder characterised by progressive neurocognitive deterioration. MPS III subtypes are clinically indistinguishable, with a wide range of symptoms and...

(This article belongs to the Section Methodology, Drug and Device Discovery)
  • Article
  • Open Access
26 Citations
4,845 Views
26 Pages

Genetic Base of Behavioral Disorders in Mucopolysaccharidoses: Transcriptomic Studies

  • Karolina Pierzynowska,
  • Lidia Gaffke,
  • Magdalena Podlacha and
  • Grzegorz Węgrzyn

10 February 2020

Mucopolysaccharidoses (MPS) are a group of inherited metabolic diseases caused by mutations leading to defective degradation of glycosaminoglycans (GAGs) and their accumulation in cells. Among 11 known types and subtypes of MPS, neuronopathy occurs i...

(This article belongs to the Special Issue Mucopolysaccharidoses: Diagnosis, Treatment, and Management)
  • Article
  • Open Access
8 Citations
6,912 Views
13 Pages

11 December 2014

Heparan sulfate (HS) catabolism begins with endo-degradation of the polysaccharide to smaller HS oligosaccharides, followed by the sequential action of exo-enzymes to reduce these oligosaccharides to monosaccharides and inorganic sulfate. In mucopoly...

(This article belongs to the Special Issue Inborn Errors of Metabolism)
  • Article
  • Open Access
4 Citations
1,972 Views
11 Pages

Intranasal Immunization with Nasal Immuno-Inducible Sequence-Fused Antigens Elicits Antigen-Specific Antibody Production

  • Hiraku Sasaki,
  • Yoshio Suzuki,
  • Kodai Morimoto,
  • Kazuyoshi Takeda and ,
  • Koichiro Uchida,
  • Masayuki Iyoda and
  • Hiroki Ishikawa
  • + 2 authors+ 0 author

28 November 2024

Intranasal immunization is one of the most effective methods for eliciting lung mucosal immunity. Multiple intranasal immunization with bacterial polypeptide, termed as a modified PnxIIIA (MP3) protein, is known to elicit production of a specific ant...

(This article belongs to the Collection Feature Papers in Molecular Immunology)
  • Article
  • Open Access
10 Citations
2,645 Views
19 Pages

Effect of Platelet-Derived Microparticles on the Expression of Adhesion Molecules in Endothelial Cells

  • Elvira Varela-López,
  • Socorro Pina-Canseco,
  • Felipe Massó-Rojas,
  • Claudia Lerma and ,
  • Ana María Mejía Domínguez,
  • Jesús Oswaldo García Ávila,
  • Juan Carlos Torres-Narváez,
  • Alvaro Vargas-González and
  • Araceli Páez-Arenas
  • + 4 authors+ 0 author

In healthy conditions and cardiovascular diseases, the most abundant microparticles (MPs) in the bloodstream are those of platelet origin, but the direct effect of these microparticles on endothelial activation is poorly understood. The objective of...

(This article belongs to the Section Molecular Pathology, Diagnostics, and Therapeutics)
  • Article
  • Open Access
10 Citations
5,018 Views
10 Pages

The Carotid Intima-Media Thickness and Arterial Stiffness of Pediatric Mucopolysaccharidosis Patients Are Increased Compared to Both Pediatric and Adult Controls

  • Raymond Y. Wang,
  • Kyle D. Rudser,
  • Donald R. Dengel,
  • Elizabeth A. Braunlin and ,
  • Julia Steinberger,
  • David R. Jacobs,
  • Alan R. Sinaiko and
  • Aaron S. Kelly
  • + 3 authors+ 0 author

Treatments for mucopolysaccharidoses (MPSs) have increased longevity, but cardiovascular disease causes mortality in a significant percentage of survivors. Markers must be developed to predict MPS cardiac risk and monitor efficacy of investigational...

(This article belongs to the Special Issue Lysosomal Storage Disorders: Novel Concepts, Therapeutic Aspects and Beyond)
  • Article
  • Open Access
61 Citations
7,099 Views
18 Pages

Brain Pathology in Mucopolysaccharidoses (MPS) Patients with Neurological Forms

  • Gustavo M. Viana,
  • David A. Priestman,
  • Frances M. Platt,
  • Shaukat Khan and ,
  • Shunji Tomatsu and
  • Alexey V. Pshezhetsky
  • + 1 author+ 0 author

1 February 2020

Mucopolysaccharidoses (MPS) are the group of lysosomal storage disorders caused by deficiencies of enzymes involved in the stepwise degradation of glycosaminoglycans. To identify brain pathology common for neurological MPS, we conducted a comprehensi...

(This article belongs to the Special Issue Lysosomal Storage Disorders: Causes, Symptoms, Diagnosis, and Treatment)
  • Article
  • Open Access
5 Citations
4,551 Views
18 Pages

Decreased Levels of Chaperones in Mucopolysaccharidoses and Their Elevation as a Putative Auxiliary Therapeutic Approach

  • Magdalena Żabińska,
  • Lidia Gaffke,
  • Patrycja Bielańska,
  • Magdalena Podlacha and ,
  • Estera Rintz,
  • Zuzanna Cyske,
  • Grzegorz Węgrzyn and
  • Karolina Pierzynowska
  • + 3 authors+ 0 author

Mucopolysaccharidoses (MPS) are rare genetic disorders belonging to the lysosomal storage diseases. They are caused by mutations in genes encoding lysosomal enzymes responsible for degrading glycosaminoglycans (GAGs). As a result, GAGs accumulate in...

(This article belongs to the Special Issue Novel Therapeutic Approaches in Rare Genetic Diseases)
  • Article
  • Open Access
3 Citations
1,948 Views
17 Pages

A Clinical–Radiomics Nomogram for the Preoperative Prediction of Aggressive Micropapillary and a Solid Pattern in Lung Adenocarcinoma

  • Xiangyu Xie,
  • Lei Chen,
  • Kun Li,
  • Liang Shi and ,
  • Lei Zhang and
  • Liang Zheng
  • + 1 author+ 0 author

Background: A micropapillary pattern (MP) and solid pattern (SP) in lung adenocarcinoma (LUAD), a major subtype of non-small-cell lung cancer (NSCLC), are associated with a poor prognosis and necessitate accurate preoperative identification. This stu...

(This article belongs to the Section Thoracic Oncology)
  • Review
  • Open Access
14 Citations
8,259 Views
13 Pages

Heparin-induced thrombocytopenia type II (HIT II), as stated in the literature, occurs in about 3% of all patients and in 0.1–5% of surgical patients. Thrombosis develops in 20–64% of patients with HIT. The mortality rate in HIT II has no...

(This article belongs to the Special Issue Advances in Platelet Biology and Functions)